MedPath

Evaluation of Non-opioid Balanced General Anesthesia in Cardiac Surgery With Extracorporeal Circulation: a Randomized, Controlled, Multicenter Superiority Trial

Phase 3
Completed
Conditions
Opioid-free Anesthesia
Cardiac Surgery
Interventions
Drug: Balanced general anesthesia without morphine
Drug: Standard general anesthesia balanced with morphine
Other: Data collection
Other: Assessment of pain
Other: Recovery quality score
Registration Number
NCT04886453
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Brief Summary

Opioid-free anesthesia (OFA) is a general anesthesia based on the use of hypnotics and non-opioid analgesics (lidocaine, ketamine, dexamethasone, esmolol). This technique has been used for the past 10 years, during which randomized and non-randomized studies have demonstrated a number of positive effects on cardiac function:

* better analgesia and decreased postoperative morphine consumption,

* better respiratory function,

* better hemodynamic stability,

* better postoperative cognitive function.

The hypothesis of the present study is that the use of OFA during cardiac surgery is associated with:

* Improved intraoperative hemodynamic stability

* A decrease in the incidence of postoperative complications

* A reduction in intensive care and hospital length of stay

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
321
Inclusion Criteria
  • Patient who has provided written and informed consent

  • Adult patient

  • Patient undergoing cardiac surgery which is:

    1. Scheduled
    2. With bypass surgery
    3. Of the following types: aortic valve surgery, mitral valve surgery, tricuspid valve surgery, atrial myxoma, coronary artery bypass surgery, aortic surgery, combined surgery
Exclusion Criteria
  • Person not affiliated to national health insurance
  • Person under legal protection (curatorship, guardianship)
  • Person under court order
  • Pregnant or breastfeeding woman
  • Adult unable to express consent
  • Patient already included once in the study
  • Patient requiring emergency surgery within 24 hours
  • Patients with hypersensitivity to local anesthetics or opiates or to any of the excipients in the products used
  • Patients on antidepressants, neuroleptics such as non-selective MAOIs (iproniazid), selective A MAOI (moclobemide), selective B MAOI (selegiline) gabapentin (Neurontin®)
  • Patients with an unprotected atrioventricular conduction disorder
  • Patients with a prolonged QTc (> 450 ms) on preoperative ECG
  • Patient with severe liver failure (PT< 30%)
  • Patient suffering from respiratory failure (Long-term oxygen therapy patient except OSA)
  • Patient with uncontrolled epilepsy
  • Patient with preoperative cognitive dysfunction (MMS <24)
  • Patient with intracranial hypertension
  • Patient with chronic kidney failure (dialysis, creatinine > 200 μmol L-1)
  • Patient with porphyria
  • Patients treated with linezolid (Zyvoxid®)
  • Patients with severe arterial hypotension (systolic BP<90 mmHg)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
InterventionBalanced general anesthesia without morphine-
InterventionData collection-
InterventionAssessment of pain-
InterventionRecovery quality score-
ControleStandard general anesthesia balanced with morphine-
ControleData collection-
ControleAssessment of pain-
ControleRecovery quality score-
Primary Outcome Measures
NameTimeMethod
Occurrence of at least one postoperative complication30 days post-surgery

Post-operative complications:

* postoperative neurological dysfunction

* acute renal failure

* acute respiratory failure

* cardiovascular complications

* death

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Chu Dijon Bourgogne

🇫🇷

Dijon, France

© Copyright 2025. All Rights Reserved by MedPath